Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences
Globe Newswire•29/10/2026•07:00 ET
0
Key Highlights
- ➤Ocular Therapeutix to participate in UBS Global Biopharma Conference on November 17
- ➤AXPAXLI remains in Phase 3 trials for wet AMD and diabetic retinal disease
- ➤Jeffrey S. Heier to present at The Empire Forum on November 5
- ➤Ocular Therapeutix executives and physicians to discuss nAMD durability at OSN New York
Expert Statements
Pravin U. Dugel, Executive Chairman, President and CEO of Ocular Therapeutix
“Ocular Therapeutix, Redefining the Retina Experience”
Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix
“Ocular Therapeutix, Redefining the Retina Experience”
BEDFORD, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming investor and scientific conferences in November 2026.
UBS Global Biopharma Conference 2026: Date: Tuesday, November 17, 2026 Fireside Chat: 12:00 – 12:30 PM GMT Presenter: Pravin U. Dugel, MD, Executive Chairman, President and CEO Location: London, UK
Get started
Create a free account to read the full story.